Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linaclotide - Ironwood Pharmaceuticals

Next Previous
Drug Profile

Linaclotide - Ironwood Pharmaceuticals

Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MD-7246; MM-416775

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Microbia
  • Developer AbbVie; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Non-opioid analgesics; Oligopeptides
  • Mechanism of Action Enterotoxin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Visceral pain

Most Recent Events

  • 05 Jun 2025 AbbVie completes a phase III trial in Irritable bowel syndrome and Constipation (In adolescents, In children, In adults) in USA, Canada, Israel and Netherlands (PO) (NCT04166058)
  • 30 Sep 2024 Discontinued - Preclinical for Visceral pain in USA (PO), before September 2024 (Ironwood Pharmaceuticals pipeline, September 2024)
  • 10 Sep 2024 Launched for Constipation (In adolescents, In children) in Canada (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top